Quarterly report pursuant to Section 13 or 15(d)

Derivative Financial Instruments

v3.10.0.1
Derivative Financial Instruments
9 Months Ended
Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Synergy Derivative Financial Instruments

Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Synergy has determined that certain warrants issued in connection with sale of its common stock must be classified as derivative instruments. In accordance with ASC Topic 815-40, these warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value are being recorded in the Company’s condensed consolidated statement of operations. The Company estimates the fair value of certain warrants using the Black-Scholes option pricing model in order to determine the associated derivative instrument liability and change in fair value.

Synergy’s warrants issued on November 13, 2017 (See Footnote 9 “Stockholders’ Deficit”) were recorded as derivative liabilities and the fair value determined using the Monte Carlo simulation.  The assumptions to determine fair value at issuance were $2.44 fair value of stock, warrant term of 2.0 years, 1.62% risk free rate, 66% volatility, and 0% dividend yield.

The assumptions used to determine the fair value of the warrants at each period end was:
September 30, 2018 September 30, 2017
Fair value of Synergy common stock
$ 1.70  $ 2.90 
Expected warrant term
1.1 years  0.4 years
Risk-free interest rate
2.13  % 1.13  %
Expected volatility
65  % 40  %
Dividend yield
—  — 

Fair value of stock is the closing market price of the Company’s common stock at the end of each reporting period when the derivative instruments are marked to market. Expected volatility is a management estimate of future volatility, over the expected warrant term, based on historical volatility of Synergy’s common stock. The warrants have a transferability provision and based on guidance provided in SAB 107 Share-Based Payment for instruments issued with such a provision, Synergy used the full contractual term as the expected term of the warrants. The risk free rate is based on the U.S. Treasury security rates for maturities consistent with the expected remaining term of the warrants at the date quarterly revaluation.

The following table sets forth the components of changes in the Synergy’s outstanding warrants which were deemed derivative financial instruments and the associated liability balance for the periods indicated:
Date  Description  Warrants 
Derivative
Instrument
Liability
(in thousands)
12/31/2017 Balance of derivative financial instruments liability  21,915,426  $ 17,582 
3/31/2018 Change in fair value of warrants during the three months ended March 31, 2018  (5,644)
3/31/2018 Expiration of warrants  (210,000) — 
6/30/2018 Change in fair value of warrants during the three months ended June 30, 2018  (2,604)
9/30/2018 Change in fair value of warrants during the three months ended September 30, 2018  433 
09/30/2018 Balance of derivative financial instruments liability  21,705,426  $ 9,767